Dang I should just erase it. No bonus as of yet. But they diluted 4 times and have n the past paid themselves a whopping $3.8M in cash and options. also notice how you gnotre the guts of my post the four dilutions. They have $8M n cash. Let's see how much remains of it.
Why didn't you comment on the fact for the past three 10-K's they spent only $110,000 on cancer. While taking in payrolls $10M+++++.
They would need something like $6M increase in revenues for the quarter. To have a GAAP profit of $1M. They only operating on a 30% profit margin and then you have depreciation, interest, taxes to get GAAP. Take the bet Spandex...this board also needs a rest from you. Tell everyone the bonehead move you made on WG.
Show us a positive one, first. How many times did they dilute in 2013. I count 4 times. Feb 28,Apr 18, july 23 and Sept 26. Most of these are unregistered sale of stock. Looks like March 14 give or take a day they should have the 10-k ready. Here's what they spent in the first 9 months of 2013
Research and development costs of $2,815,519 for the nine months ended September 30, 2013 included payroll of $1,135,095, consulting and contract labor of $1,006,049, legal of $174,539, insurance of $148,549, lab supplies and pharmaceutical preparations of $290,921, rent and utilities of $55,716, and depreciation expense of $4,650. Research and development costs of $4,352,940 for the nine months ended September 30, 2012 included payroll of $2,258,622, consulting and contract labor of $1,737,376, legal of $178,236, insurance of $85,228, lab supplies and pharmaceutical preparations of $32,564, rent and utilities of $56,335, and depreciation expense of $4,579. The decrease in payroll is the result of no bonuses being paid during the nine months ended September 30, 2013. The decrease in consulting and contract labor is due to decreased costs of current preclinical and clinical trial activity. The increase in lab supplies and pharmaceutical preparations is the result of securing drug substance and drug product for pivotal clinical studies with the newly patented synthesis of Rose Bengal.
Notice two different figures for payroll. Amazing how much this company spends on this item. I'll be looking at how much they spent on Melanoma, liver and other cancers in 2013. We know they spent Zero the previous two years. You have to go back to 2010 to find any costs spent on any cancer in the 10-k. A whopping $110K for Liver and Zero for Breast and melanoma. Are they paying Moffit with stock? Wonder is the CEO makes another large bonus this year?
Spandex was bragging he sold WG at $8.25 range. Today the stock over $10.75. I tried to educate him. So you have to understand that he's not in a good mood. Now we just got to figure out when to short this pig.
A few months back I sold some stock I had in PZZI at $8.90 and rolled into WG. I timed that well. I now sold that position only in WG and bought back PZZI. Pocket $29K. Now I'm hoping PZZI is about to get it's legs back. They have a neat concept to cook a pizza in 5 minutes. I have tasted it and it's great. They have 20 P5 stores open and what we're hearing is the Florida location is on fire. The owner of this franchise wants to open 25 in Florida. A group just commented to opening 38 in the Washington DC area.
I'm a little disappointed that more stores haven't already opened, they have a franchise commitment for 150 stores. But this could be a huge growth story. They had some turn over in management, that has taken the wind out of the sails. But we're waiting on who they replace them with. PZZI has been around for many years, this new venture they started is called Pie Five. The reviews on twitter are tremendous. Happy that WG has broken above your technical points. They have one quarter to get by and then this races towards $20.
I sold some at $10.60. I love this stock, but they do have a iffy quarter to get past. Still believe we see $15-$20 this year. I want to go back and look at the full 2013 earnings and see if I can estimate the 2014 numbers. We have a few one time events last year that impacted earnings that we will not see this year. I still hold a substantial number of shares. I want to show spandex by looking back can actually be looking forward. He seems to not grasp that concept.
Leaving? I have other investments like OPK, WG and PZZI that have real earnings and growth potentials. This is a distraction, but one that deserved a second look. But I feel comfortable that I made the right decision. I believe longs need to be careful listening to amateurs who last week were pumping FNMA. I feel this board is a few posters using multiple ids and have no back ground what so ever on a biotech. They make excuses for everything. Normally I can find something positive, but this looks like a company ran by low level operatives who line their pockets first.
I hope that combination isn't a set back. Some see BTD as a short cut, I see it as excuse. I reserve the right to post a response to attacks and misinformation. So the odds that this is my last post here is slim to none.
I don't have to. This is a ph1 study with 3-6 patients. It is a set back, since it looks like they had to change directions. There are no assurances that combination will work. If plan A doesn't work plan B is 5 years from now. If you call that progress, that's your decision . I just don't see it that way.
Opens the door for 95% of patients to get the drug? Interesting, are you saying that only 5% will get it if BTD is approved? That makes sense. Thanks for making my point on who exactly will benefit from RB if BTD is granted.
To clarify my points, since Eckgars has spent so much time finally reading the 10-K. How much did they spend on Melanoma and Liver cancer in 2011 and 2012. ZERO$$$$$. Apparently they were partying after getting that huge bonus in 2010 of $2M that they spent nothing the following years on any cancer.
Do you feel it's right that the CEO granted $3.8M of investors money in 2010 and what exactly did those clinical results materialize over the next 4 years. Did they dilute after taking these bonuses?
I don't have to twist nothing. It's clear to see. Once you take the blinkers off. I'm sorry that I cannot buy the hype. It looks weak and designed to influence the naïve investor. That is my opinion. To date I see nothing that strikes ME as a buying opportunity. Does that mean I'm right....heck no. Is the PH1 on Liver something that you could see revenues in the next 3 years...I don't think so, since they are in Ph1 with only 3-6 patients.
I hope this works out for longs. I did my DD and I'm passing on it. I just don't like it when a company goes out of their way to add to speculation. That's only my opinion. You are welcome to yours.
Whatever the outcome good or bad you will learn something. I'm not here to destroy anyone's dreams.
The earnings would have been worse had they not sold the profitable stock. This would have been a .09 cent loss otherwise. But maybe they have some news and now that earnings out of the way, they can talk about it.
On January 2, 2013, Glenn Kleba, derivatively on behalf of the Company as a nominal defendant (the “Plaintiff”), filed a shareholder derivative complaint in the Circuit Court for the State of Tennessee, Knox County, against H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Stuart Fuchs, Kelly M. McMasters, Alfred E. Smith, IV and Peter R. Culpepper, and against the Company as a nominal defendant (the “Shareholder Derivative Complaint”). The Shareholder Derivative Complaint alleges (i) breach of fiduciary duties, (ii) waste of corporate assets, and (iii) unjust enrichment, all three claims based on the Plaintiff’s allegations that the defendants authorized and/or accepted stock option awards in violation of the terms of the Company’s 2002 Stock Plan (the “Plan”) by issuing stock options in excess of the amounts authorized under the Plan and delegated to defendant H. Craig Dees the sole authority to grant himself and other executive officers of the Company cash bonuses that the Plaintiff alleges to be excessive.
The Company intends to defend vigorously against all claims in this complaint. However, in view of the inherent uncertainties of litigation and the early stage of this litigation, the outcome of this case cannot be predicted at this time. Likewise, the amount of any potential loss cannot be reasonably estimated.
I cannot think of anything this company has done to me. Financially I made 44% return in less than 36 hours. I stay around because of the behavior of a few. But Bigguy you're entitle to your opinion. So am I. Think what you want. I just do not share your enthusiasm and I post what I don't like. You can ignore everything. Somehow your little company who over paid themselves in 2010 and claimed it was for clinical things they have accomplished. Then 4 years later we are still waiting. That sounds logical.
I love how so many id's all get the same brain fart, that I repeat myself. I guess repeating that I'm repeating will some how discourage me. I don't think so. But watch and learn. I was going to go softly into the night, but screw that. Now I roll up my sleeves and really give you both barrels.
Management claiming they didn't take wages. LOL. They actually gave themselves a $2M bonus and $1.8M in options. Maybe this is what the lawsuit was about? I will find the lawsuit stuff in a few minutes, maybe you can start working on a excuse.
I was out of it. I was very happy with better than 5% profit. Now I looking at shorting it again, specially going into earnings. If the company keeps the late date, this is a no brainer. Now if they change the date, I would wait.
I went back and looked at payroll expense for the past 5 years. Earlier today Vorlon stated that the insiders went without pay, but that is not true. They actually in 2010 gave themselves huge amount of money. No where in the 10-k's does it state that they ever went without compensation. I went back as far as 2008.
Here's the excuse they used in 2010 to explain the 2009 and 2010 differences in costs. 2009 payroll $2.86M and 2010 $6.6M. Interesting how they explained this.
The increase in payroll in 2010 over 2009 is primarily due to increased bonuses of approximately $2,000,000 and increased stock option expense of approximately $1,800,000, both of which increased due to the significant progress made in the clinical development program for both our oncology and dermatology drug product candidates. The decrease in consulting and contract labor in 2010 versus 2009 is primarily due to receipt of a grant for approximately $244,000 under the Qualifying Therapeutic Discovery Project Program.
This doesn't sound like they went without pay. Brings into question what Vorlon stated they explained. Well it seems that not only are longs good at excuses, so are management. Wanted to stay away but these nagging questions. was this company in 2010, doing the same thing they seem to be doing today. What I mean announcing in 2010 that they wanted to reward themselves for clinical achievement from 2010. Did the longs back then read more into this move?
I will look into what salaries were listen on previous 10-k's. Not that I don't trust your information, but I hear so many excuses. There is a lawsuit outstanding when investors question the amount of shares they rewarded themselves. It was unsettled as of Dec 2012.
I view the ph1 trial in liver as a major set back. I don't see any real credentials on anyone of the insiders. Dr. Wachter is just a chemist. Attended the University of Wisconsin. Go Badgers. Too many lose ends here to get really excited.
Miracle drug setting the bar as low as they can. I warned investor what I got out of the EOC was combination maybe needed. I believe you have to watch what they say discreetly, as the truer picture. I constantly find information on their web page that references mice data. I have no doubt mice see benefits here, however the human body is a whole different game.
Sometimes you have to get hit over the head before waking up. I ask that the pumpers behave and I will not return. However, if you want to continue to insult, I can and will resume my DD. You don't like when I post my findings, it leaves you with a huge goose egg. For the few investors who have concerns, be careful, the pumpers were stocking shelves before coming here.
Let's be realistic here and take the average between these two interesting predictions. $4 and $50. The average is $27. That sounds about right. Just kidding. I'm sure Den56kk and this new poster are here in hopes of getting some cheap shares before this really takes off. Today there were several new- opening soon indications on their web site and looks like Virginia is just about ready.
Growth is definitely slower than we wanted. But the success of the Port orange store was a huge leg up. This will pick up steam and we could easily see $15 this year. I bet if you tracked any new franchise, they all performed at the same pace of openings. You walk before you run. Soon we will have 25 opened P5, each contributing to the earnings statement. If they do some dilution, it's for the right reasons, more stores. If 10M shares outstanding , means about $10M in working capital great. This would open maybe 30 company stores in the Atlanta and Colorado area. Then they have the beginning of a central location to deliver supplies to the stores. That's how dominoes makes 75% of their profits.
I would not rule out some very big news.
I disagree. You are getting set up for a big no event. If you cannot see that, then maybe I have to post more. Have you read the 10-k? Something stinks here besides the numerous posts asking concerned investors, why we post. We post because you can not sell this garbage and not expect some tough questions. The pumpers were the ones stating PFE sat on the board. I'm the one that questioned this and now we know they are only paid advisors.
My theory is this is all a ruse, this company has supplied a load of misinformation at one time. I'd be careful if so many things are all made known at the same time, specially after realizing that the drug has actually started over.
The pumpers here want the Liver trial to sound like a great move. but in reality it meant your drug doesn't have the guts in it, to go alone. That in melanoma the trial fell short in Primary and secondary endpoints and they had to go digging for something positive. I just take the disinformation and paint the truth about it. Pumpers and longs don't want to hear anything contradicting. I on the other hand want to make sure the pump is exposed. As for Eckgars, no amount of negative posts by any fake ID here will persuade me to not expose this individual.
Here is a piece on the going rate for Hepatitis drug
Gilead’s drug, Sovaldi, was approved in December, and is among the first of a new wave of hepatitis C treatments that can cure the liver disease faster and more reliably than previous drugs. Sovaldi, which costs $84,000 for a 12-week course of treatment, is expected to produce $4.2 billion in revenue this year, rising to $8.1 billion in 2015, according to the average estimate of 13 analysts surveyed by Bloomberg.
Company is not shy about events. They are shy about following through on things. I find it strange that in small space of time this company made sure that numerous things are well known. They appoint to a paid position an advisor who works for a big pharma. They announce BTD and patent announcement. name change and numerous old information Pr's, about mice results. Why not a type A or B meeting? The company usually come's clean somewhere in their Pr's, you just have to look deeper at them. Who normally doesn't read the fine print, greedy investors would be my guess. This is why no institution ownership. Could this company pump this, if they had deep pockets holding shares?
Now Photogen is when 75% of the insiders came from. This company leases month to month their building. Allocated no cost to Melanoma and Liver in 2011 and 2012. Interesting that investors had action against the company for granting excessive shares to themselves, that weren't allowed under the articles. Look at the 10-k.
So not only did these insiders take big checks they took liberty with stock options. They must of felt they were under paid. I believe they came to the realization that the road to approval would now have to start over with a ph1 combination trial. That ph3 wasn't an option. But with a few publically news items, then may be able to generate some hype. They are careful to notify investors, so not their fault if you want to conjure up more to it.
One day you can be pumping FNMA and next week making a prediction of $6 and then to .80 here. Having to scramble and erase that post. Sounds like an honest group here, as long as they get theirs first. Maybe that's what attracts them here, how management who really didn't follow through, however took large salaries.
Excuses is what you want this is the board for you. Hundreds of excuses.
Your welcome. You'll be back bragging you bought lower if that happens. I actually believe we would be up higher, if your strong market opinion wasn't down 200 Pts. I'll be happy if we hold onto this range till the spring when things will get very good.